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counted for 1.5 percent of the average cost of admission
($125 of $7974 total cost, 90% CI: $96–$224). Relative
to no prophylaxis, the incremental cost per VTE avoided
using enoxaparin was $1330  468.
CONCLUSIONS: Acutely ill medical patients are at high
risk of VTE with treatment costs ranging from approxi-
mately $2500 (outpatient) to $25,000 (inpatient). Chronic
care for post-thrombotic syndrome, experienced in 20%-
56% of deep vein thrombosis patients further increases
the cost burden. This analysis demonstrates that VTE
prophylaxis with enoxaparin, in acutely ill medical pa-
tients has both economic and clinical benefits.
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OBJECTIVES: Cerebrovascular accidents (CVA) affect
120,000 French people each year. The aim of the study
was to calculate the cost of managing these patients.
METHODS: A Markov model was used in which four
clinical conditions were distinguished: first ischaemic
event; first cerebral haemorrhage; recurrent ischaemic
event; recurrent haemorrhagic event. Three lines of man-
agement were identified after hospitalisation: rehabilita-
tion, home, and geriatric institutions. Three levels of in-
capacity were identified using the Barthel index. Patients’
pathways in the health-care system were identified from
the only French register (Dijon) related to this disease
The specific death rates were calculated at 3, 6, 9 and 12
months. The severity of sequelae was assessed using the
Barthel index at 3 and 12 months. The clinical benefit
was measured as survival without loss of independence
(Barthel 95-100). All of the cost calculations were made
from the perspective of the community. Expenditures
were discounted at a rate of 5%.
RESULTS: The time horizon used for the model was five
years. 54.7% of the patients died during this time. The
average incapacity times after hospitalization over the
five years were: 70% slight incapacity (Barthel 95-100);
15% moderate incapacity (Barthel 60-90), and 15% se-
vere incapacity (Barthel 0-55). The total cost of manag-
ing the 120,000 cases of cerebrovascular accidents was
approximately 17 billion francs over the five years fol-
lowing the event. Twenty four percent (4.1 billion FF) of
this cost was related to short-term hospitalizations, 16.5%
(2.8 billion FF) to admissions to re-education or rehabili-
tation institutions, 33% (5.6 billion FF) to institutional
management, and 26.5% (4.5 billion FF) to looking after
patients at home. A sensitivity analysis was conducted
specially frequency with which health-care professionals
visited the patients at home.
CONCLUSION: This method allows for the calculation of
long-term costs of new cases of cerebrovascular accident.
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OBJECTIVE: The aim of the study was to assess the
costs and cost distribution of hypertension in Poland and
to compare the societal burden of hypertension on an in-
ternational basis.
METHODS: The time horizon of the analysis was 12
months and a retrospective approach was applied. The direct
medical costs of pharmacological treatment, doctor consulta-
tions, laboratory and diagnostic tests and hospitalizations
were identified and calculated. Indirect costs due to lost pro-
ductivity were also included in the analysis. All of the cost
components were collected with the aid of a cost assessment
formula, which was included in the epidemiological protocol.
RESULTS: Based on data collected from 9286 patients, the
average cost per hypertensive patient per year was calcu-
lated at 1570 PLN. The total burden of hypertension in
Poland may reach as much as 14 billion PLN per year. The
distribution of total costs is as follows: pharmacological
treatment, 10.2%; doctor consultations, 30.8%; labora-
tory and diagnostic tests, 11.4%; hospitalizations, 21.0%,
and productivity loss, 26.6%. An international compari-
son demonstrated that expenditures incurred as a result of
the pharmacological treatment of hypertension in Poland
were much lower than in other countries (i.e. Sweden:
53.3%, USA: 20.7%). Theoretically the total burden of
hypertension on society per year amounts to 31 USD in
Sweden, 82 USD in the United States and 88 USD in Po-
land using exchange rates available on January 21, 2000.
CONCLUSION: The results of the analysis demonstrate
that hypertension constitutes an important economic
burden for the Polish population. The cost of pharmaco-
logical treatment represents the lowest percentage of the
total cost of hypertension and the smallest portion of di-
rect medical costs. The conclusion is that an optimal allo-
cation of expenditure for pharmacological treatment may
contribute to a significant reduction of the total cost of
hypertension following the example of other European
countries such as Sweden as well as the United States.
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OBJECTIVE: To study costs and effectiveness of com-
mon practice treatment for critical limb ischemia at Mos-
cow hospitals.
METHODS: Data was obtained from 105 medical charts
from six Moscow hospitals. Inclusion criteria were: criti-
